[go: up one dir, main page]

MX2019003467A - Formulaciones y metodos para la administracion vaginal de antiprogestinas. - Google Patents

Formulaciones y metodos para la administracion vaginal de antiprogestinas.

Info

Publication number
MX2019003467A
MX2019003467A MX2019003467A MX2019003467A MX2019003467A MX 2019003467 A MX2019003467 A MX 2019003467A MX 2019003467 A MX2019003467 A MX 2019003467A MX 2019003467 A MX2019003467 A MX 2019003467A MX 2019003467 A MX2019003467 A MX 2019003467A
Authority
MX
Mexico
Prior art keywords
antiprogestins
methods
formulations
vaginal delivery
present
Prior art date
Application number
MX2019003467A
Other languages
English (en)
Other versions
MX382986B (es
Inventor
S Podolski Joseph
Hsu Kuang
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MX2019003467A publication Critical patent/MX2019003467A/es
Publication of MX382986B publication Critical patent/MX382986B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La materia objeto de la presente invención es pertinente al campo de la administración vaginal de agentes farmacéuticamente activos. Modalidades de la presente invención describen métodos para tratar una variedad de trastornos relacionados con progesterona por la administración vaginal de una cápsula de pululano que comprende una o más antiprogestinas.
MX2019003467A 2012-05-31 2013-05-30 El uso de una cápsula mucoadherente que comprende pululano y cdb-2914 para el tratamiento de un trastorno dependiente de la progesterona MX382986B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653674P 2012-05-31 2012-05-31
PCT/US2013/043447 WO2013181449A1 (en) 2012-05-31 2013-05-30 Formulations and methods for vaginal delivery of antiprogestins

Publications (2)

Publication Number Publication Date
MX2019003467A true MX2019003467A (es) 2019-06-06
MX382986B MX382986B (es) 2025-03-13

Family

ID=48614182

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014014054A MX363640B (es) 2012-05-31 2013-05-30 Formulaciones y metodos para la administracion vaginal de antiprogestinas.
MX2019003467A MX382986B (es) 2012-05-31 2013-05-30 El uso de una cápsula mucoadherente que comprende pululano y cdb-2914 para el tratamiento de un trastorno dependiente de la progesterona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014014054A MX363640B (es) 2012-05-31 2013-05-30 Formulaciones y metodos para la administracion vaginal de antiprogestinas.

Country Status (22)

Country Link
US (1) US10328022B2 (es)
EP (1) EP2854763B1 (es)
JP (1) JP6341910B2 (es)
KR (1) KR102127348B1 (es)
CN (1) CN104334158B (es)
AU (1) AU2013267359C1 (es)
BR (1) BR112014029131B1 (es)
CA (1) CA2872644A1 (es)
CL (1) CL2014003232A1 (es)
CO (1) CO7141411A2 (es)
CR (1) CR20140567A (es)
EA (1) EA030444B1 (es)
ES (1) ES2701400T3 (es)
IL (1) IL235450B (es)
IN (1) IN2014DN10548A (es)
MX (2) MX363640B (es)
NZ (1) NZ702467A (es)
PH (1) PH12014502516B1 (es)
SG (2) SG11201407397WA (es)
UA (1) UA114106C2 (es)
WO (1) WO2013181449A1 (es)
ZA (1) ZA201408262B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3139908A4 (en) * 2014-05-05 2018-05-16 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11623008B2 (en) 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
WO2016064873A1 (en) * 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3025709B1 (en) 2014-11-27 2020-09-30 Capsugel Belgium NV Dosage form articles for external mucosal applications
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan
AU2018251256B2 (en) * 2017-04-14 2023-10-05 Capsugel Belgium Nv Pullulan capsules

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
JPH10512889A (ja) 1995-02-02 1998-12-08 シェーリング アクチェンゲゼルシャフト 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
ATE194358T1 (de) 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-substituierte progesteron derivate als antigestagene
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
AU4584901A (en) 2000-03-17 2001-10-15 Us Gov Health & Human Serv Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (es) 2000-03-28 2003-09-13 Dabur Res Foundation
PL360151A1 (en) 2000-10-18 2004-09-06 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
ATE406153T1 (de) 2001-07-09 2008-09-15 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
AU2002329842B2 (en) 2001-08-29 2006-09-14 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
JP2003143474A (ja) 2001-11-02 2003-05-16 Matsushita Electric Ind Co Ltd 映像信号処理システム
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
MX2007000273A (es) 2004-07-09 2007-05-21 Population Council Inc Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona.
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CA3071412A1 (en) 2005-03-22 2006-09-28 Allergan Pharmaceuticals International Limited Dosing regimes for trans-clomiphene
CA2604218A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US20090149434A1 (en) * 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
CN1846703A (zh) 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
US8173626B2 (en) 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
KR20070116538A (ko) * 2006-06-05 2007-12-10 유겐가이샤 코리츠 쇼지 삽입 보조 기구
JP2008012281A (ja) * 2006-06-05 2008-01-24 Koritsu Shoji:Kk 挿入補助器具
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
ES2643318T3 (es) 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
AU2008237246B2 (en) * 2007-04-05 2014-06-05 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
HRP20160689T1 (hr) 2007-04-20 2016-07-15 Preglem S.A. Selektivni modulatori progesterona za tretman uterinog krvarenja
ES2467942T3 (es) 2007-09-20 2014-06-13 Lapidot Medical Import And Marketing Ltd Composiciones y medios para tratar leiomiomas uterinos, leiomioma, mioma, fibroides uterinos, endometriosis, adenomiosis y trastornos relacionados por mifepristona.
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
JP5992330B2 (ja) * 2009-09-29 2016-09-14 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 物質を投与するための子宮内電子カプセル
UA113283C2 (xx) 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
WO2012121767A1 (en) 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування

Also Published As

Publication number Publication date
US10328022B2 (en) 2019-06-25
ZA201408262B (en) 2015-12-23
UA114106C2 (xx) 2017-04-25
CR20140567A (es) 2015-03-09
EA201492290A1 (ru) 2015-03-31
KR20150014928A (ko) 2015-02-09
BR112014029131A2 (pt) 2018-05-29
IN2014DN10548A (es) 2015-08-21
US20150111862A1 (en) 2015-04-23
SG11201407397WA (en) 2014-12-30
IL235450A0 (en) 2014-12-31
IL235450B (en) 2020-02-27
EA030444B1 (ru) 2018-08-31
BR112014029131B1 (pt) 2021-03-09
KR102127348B1 (ko) 2020-06-29
NZ702467A (en) 2016-07-29
CA2872644A1 (en) 2013-12-05
ES2701400T3 (es) 2019-02-22
PH12014502516A1 (en) 2015-01-12
JP2015518052A (ja) 2015-06-25
AU2013267359C1 (en) 2016-09-29
EP2854763B1 (en) 2018-09-26
CN104334158A (zh) 2015-02-04
CL2014003232A1 (es) 2015-03-13
AU2013267359B2 (en) 2016-05-26
EP2854763A1 (en) 2015-04-08
AU2013267359A1 (en) 2014-11-20
JP6341910B2 (ja) 2018-06-13
PH12014502516B1 (en) 2015-01-12
WO2013181449A1 (en) 2013-12-05
CO7141411A2 (es) 2014-12-12
CN104334158B (zh) 2018-08-10
HK1206622A1 (en) 2016-01-15
MX363640B (es) 2019-03-28
MX2014014054A (es) 2015-02-12
SG10201704858PA (en) 2017-07-28
MX382986B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
UA124922C2 (uk) Модулятори ядерного транспорту та їх застосування
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2020005921A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
ECSP15025868A (es) Composición que comprende un extracto purificado aíslado de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir/tratar la enfermedad pulmonar obstructiva crónica, y su uso
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах